MADRID – Specific antiphospholipid antibodies have differing influences on the manifestations of two important autoimmune diseases.
NEW ORLEANS – National Inpatient Sample data showed that during 2004-2015 hospitalized U.S. patients with a PE diagnosis jumped by 80%.
Only one deep-vein thrombosis and no pulmonary embolism occurred in 3 months of follow-up in nearly 500 women.
SEATTLE – Two studies detail the risk factors of first-time venous thromboembolism and heightened incidence of repeat VTE in patients with HIV.
CHICAGO – A computerized decision support system increased anticoagulation rates and reduced cardiac event rates in at-risk atrial fibrillation...
The rate of major bleeding was similar with apixaban and dalteparin.
MONTREAL – A randomized trial got derailed by underrecruitment and crossovers, but still showed evidence of thrombectomy’s efficacy.
CHICAGO – Ethnicity and limb infection are independent predictors of poor outcomes, including limb amputation, in TAO.
Cancer patients treated with apixaban had a significantly lower rate of venous thromboembolism but a higher risk of major bleeds than did those...
CHICAGO – Insurance claims data from more than 50,000 U.S. octogenarians on a DOAC showed apixaban worked best and caused the fewest major bleeds...
MONTREAL – The new EXTEND findings “will have a major impact” on using an extended time window for thrombolysis in U.S. practice.
MUNICH – Results from a worldwide registry with more than 26,000 atrial fibrillation patients showed better survival with a direct oral...
Oral anticoagulation threshold according to CHA2DS2-VASc score varied widely after accounting for varying stroke rates in published studies.
The new guidelines highlight 60 key recommendations from the 12-person expert panel.
PARIS – Swedish registry report analyzes key clinical outcomes in more than 36,000 consecutive acute MI patients who received newer-generation...
MALMO, SWEDEN – Recognition of key risk factors warrants early screening ultrasound.
The obesity paradox makes a showing in the risk of all-cause death.
A reanalysis of the ATLAS ACS 2-TIMI 51 trial separated fatal and nonfatal events.
PARIS – “Given the high bleeding risk, single antiplatelet therapy seems to be a good option for these patients,” said Dr. Ulf Landmesser.
